Efficacy of Covexir® (Ferula foetida oleo‐gum) treatment in symptomatic improvement of patients with mild to moderate COVID‐19: A randomized, double‐blind, placebo‐controlled trial

The SARS‐CoV‐2 COVID‐19 pandemic has emerged as an unprecedented emergency state in healthcare system and global challenge. In recent decade, the function of exogenous H2S in the treatment of respiratory diseases has been investigated using H2S‐donor agents. Ferula foetida is a medicinal plant that is traditionally used in respiratory diseases including asthma and viral respiratory diseases. The oleo‐gum of this plant is a rich source of several organic sulfides including thiophenes, disulfides and polysulfide derivatives, which can act as H2S‐donor agents. The purpose of this study was to investigate the efficacy of Covexir® (F. foetida oleo‐gum) treatment as a rich source of H2S‐donor compounds in clinical presentations of patients with COVID‐19. The efficacy of Covexir® was evaluated in a randomized, double‐blind, placebo‐controlled trial in outpatients with COVID‐19. Covexir® could significantly inhibit cough when compared to the placebo group (p